New Weight-Loss shot enters first human safety trial

NCT ID NCT07518589

Not yet recruiting Disease control Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests an experimental drug called CMS-D008 in 110 healthy and overweight or obese adults. The main goal is to check safety and how the body processes the drug, not weight loss. Participants will receive either the drug or a placebo as injections, and researchers will monitor vital signs, lab tests, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CMS-D008 (an experimental biologic injection)

What this could lead to

If successful, this could point toward a new treatment for weight management in overweight or obese adults.

What could go wrong

This is a very early Phase 1 trial focused on safety, not weight loss. It is small (110 people) and may not show meaningful benefits or lead to a marketed drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EVALUATE THE SAFETY AND TOLERABILITY HEALTHY AND OVERWEIGHT OR OBESE PARTICIPANTS